The ABC of Epstein-Barr virus infections

Advances in Experimental Medicine and Biology

Volumn 568, Issue , 2005, Pages 25-39

  Allen, Upton D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; B LYMPHOCYTE ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; STEROID;

B LYMPHOCYTE; BIOLOGICAL MODEL; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE SYSTEM; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INFECTION; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; NUCLEIC ACID ANALYSIS; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROLOGY; SPACE FLIGHT; VIRUS GENE; VIRUS INFECTION; VIRUS LOAD; VIRUS TRANSMISSION; X CHROMOSOME LINKED DISORDER; ARTICLE; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; VIRUS CELL TRANSFORMATION;

HUMAN HERPESVIRUS 4;

CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS;

EID: 25144464924     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-25342-4_3     Document Type: Review

References (63)

1. Allen, U., Farkas, G., Hébert, D., Petric, M., Tellier, R., Ngan, B. et al. (2001a). Post-transplant lymphoproliferative disorder (PTLD) in children: Risk factors and associated features. In Program and Abstracts, 39th Annual Meeting of the Infectious Diseases Society of America. Abstract #306, 91.
2. Allen, U., Hébert, D., Petric, M., Tellier, R., Tran, D., Superina, R. et al (2001 b). Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin. Infect. Dis. 33, 145-150.
3. American Academy of Pediatrics. (2003). Epstein-Barr virus infections. 26th Edn. L.K. Pickering, ed. Red Book: 2003 Report of the Committee on Infectious Diseases, Elk Grove Village, IL, 271-273.
4. Bar, R.S., Delor, C.J., Clausen, K.P., Hurtubise, P., Henle, W., and Hewetson, J.F. (1974). Fatal infectious mononucleosis in a family. New Engl. J. Med. 290, 363-367.
5. Basgoz, N. and Preiksaitis, J.K. (1995). Post-transplant lymphoproliferative disorder. Infect. Dis. Clin. N. Am. 9, 901-923.
6. Brooks, L.A., Lear, A.L., Young, L.S., Rickinson, A.B. (1993). Transcription from the Epstein-Barr virus BamH1A fragment are detectable in all three forms of virus latency. J. Virol. 67, 3182-3190.
7. Carpentier, L., Tapiero, B., Alvarez, F., Viau, C., and Alfieri, C. (2003). Epstein-Barr virus (EBV) early antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J. infect. Dis. 188(12), 1853-1864.
8. Chen, H., Smith, P., Ambinder, R.F., Hayward, S.D. (1999). Expression of Epstein-Barr virus BamH1-A rightward transcripts in latently infected B cells from peripheral blood. Blood 93, 3026-3032.
9. Cockfield, S.M., Preiksaitis, J., Harvey, E., Jones, C., Hébert, D., Keown, P., et al (1991). Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc. 23, 1106-1107.
10. Cogoli, A. (1993). The effect of space flight on human cellular immunity. Environ. Med. 37, 107-116.
11. Cohen, J.I. (2000). Epstein-Barr virus infection. N. Engl. J. Med. 343, 481-492.
12. Collins, M.H., Montone, K.T., Leahey, A.M., Hodinka, R.L., Salhany, K.E., Kramer, D.L., et al (2001). Posttransplant lymphoproliferative disease in children. Pediatr. Transplant. 5, 250-257.
13. Cox, K.L., Lawrence-Miyasaki, L.S., Garcia-Kennedy, R., Lennette, E.T., Martinez, O.M., Krams, S.M et al (1995). An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59, 524-529.
14. Dror, Y., Greenberg, M., Taylor, G., Superina, R., Hébert, D., West, L. et al (1999). Lymphoproliferative disorders post organ transplant in children. Transplantation 67, 990-998.
15. Eliopoulos, A.G. and Young, L.S. (1998). Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16, 1731-1742.
16. Epstein, M.A., Achong, B.C., Barr, Y.M. (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 15, 702-703.
17. Epstein, M. A. (2001). Reflections on Epstein-Barr Virus: Some Recently Resolved Old Uncertainties. J. of Infection 43, 111-115.
18. Farrel, P.J. (1995). Epstein-Barr virus immortalizing genes. Trends Microbiol. 67, 3182-3190.
19. Faulkner, G.C., Burrows, S.R., Khanna, R., Moss, D.J., Bird, A.G., and Crawford, D.H. (1999). X-linked agammaglobulinemia patients are not infected with Epstein-Barr virus: Implications for the biology of the virus. J. Virol. 73, 1555-1564.
20. Fingeroth, J.D., Weis, J.J., Tedder, T.F., Strominger, J.L., Biro, P.A., and Fearson, D.T. (1984). Epstein-Barr virus receptor of human B lymphocytes in the C3d receptor CR2. Proc. Natl Acad. Sci. USA 81, 4510-4514.
21. Green, M., Cacciarelli, T.V., Mazariegos, G.V., Sigurdsson, L., Qu, L., Rowe, D.T. et al (1998). Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 66, 1641-1644.
22. Green, M., Kaufman, M., Wilson, J., and Reyes, J. (1997). Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin. Infect. Dis. 25, 1344-1349.
23. Green, M. and Michaels, M. (2001). Predicting outcome from post-transplant lymphoproliferative disease: A risky business. Pediatr. Transplant. 5, 235-238.
24. Green, M. and Webber, S. (2003). Posttransplant lymphoproliferative disorders. Pediatr. Clin. N. Am. 50, 1471-1491.
25. Henle, W., Diehl, V., Kohn, G., Zur Hausen, H., and Henle, G. (1967). Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt's cells. Science 157, 1064-1065.
26. Henle, W. and Henle, G. (1980). Epidemiologic aspects of Epstein-Barr virus (EBV)-associated diseases. Ann. NY Acad. Sci. 354, 326-331.
27. Ho, M. (1995). Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant. Proc. 27, 38-40.
28. Ho, M., Miller, G., Atchison, R.W., Breinig, M.K., Dummer, J.S., Andiman, W. et al (1985). Epstein-Barr virus infection and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: Role of primary infection. J. Infect. Dis. 152, 876-886.
29. Hsu, D.H., de Waal Malefyt, R., Fiorentino, D.F., Dang, M.N., Vieira, P.. de Vries, J. et al (1990). Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 2560, 830-832.
30. Izumi, K.M. and Kieff, E.D. (1996). The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factors-associated death domain protein to mediate B lymphocyte growth transformation and activate NK-kB. Proc. Natl. Acad. Sci. USA 94, 12592-12597.
31. Kenagy, D.N., Schlesinger, Y., Wesk, K., and Ritter, J.H. (1995). Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 60, 547-554.
32. Konstantinova, I.V. (1991). Immune resistance of man in space flights. Acta Astronaut. 23, 123-127.
33. Li, Q., Spriggs, M.K., and Kovats, S. et al. (1997). Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol. 71, 4657-4664.
34. Macsween, K.F. and Crawford, D.H. (2003). Epstein-Barr virus-recent advances. Lancet 3, 131-140.
35. Martinez, O.M., Villanueva, J.C., Làwrence-Miyasaki, L., Quinn, M.B., Cox, K., and Krams, S.M. (1995). Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 59, 519-524.
36. McDiarmid, S.V., Jordan, S., Kim, G.S., Toyoda, M., Goss, J.A., Vargas, J.H. et al (1998). Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66, 1604-1611.
37. Moore, K.W., O'Garra, A., de Waal Malefyt, R., Vieira, P., and Mosmann, T.R. (1993). Interleukin-10. Annu. Rev. Immunol. 11, 165-190.
38. Okano, M. (1998). Epstein-Barr virus infection and its role in the expanding spectrum of human diseases. Acta Paediatr. 87, 11-18.
39. Okano M. (2000). Haematological associations of Epstein-Barr virus infection. Bailliere's Clinical Haematology 13, 199-214.
40. Okano, M. and Gross, T.G. (2001). From Burkitt's lymphoma to chronic active Epstein-Barr virus (EBV) infection: An expanding spectrum of EBV-associated diseases. Pediatr. Hematol. Oncol. 18, 427-442.
41. Patel, R., Snydman, D.R., Rubin, R.H., Ho, M., Pescovitz, M., Martin, M. et al. (1996). Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61, 1279-1289.
42. Payne, D.A., Mehta, S.K., Tyring, S.K., Stowe, R.P., Pierson, D.L. (1999). Incidence of Epstein-Barr virus in astronaut saliva during spaceflight. Aviat. Space Environ. Med. 70, 1211-1213.
43. Petti, L. and Kieff, E. (1988). A sixth Epstein-Barr virus nuclear antigen (EBNA 3B) is expressed in latently infected growth-transforming lymphocytes. J. Virol. 62, 2173-2178.
44. Pierson, D.L. (2004). http://spacebio.net/modules/mb_resource/microbes/ tsld001.htm, accessed November 8, 2004.
45. Pope, J.H., Horne, M.K., and Scott, W. (1968). Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer 3, 857-866.
46. Preiksaitis, J.K., Diaz-Mitoma, F., Mirzayans, F., Roberts, S., Tyrrell, D.L.J. (1992). Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serological responses, and the risk of post-transplant lymphoproliferative disorder. J. Infect. Dis. 166, 986-994.
47. Preiksaitis, J.K. and Keay, S. (2001). Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. CID 33, S38-S46.
48. Purtillo, D.T., Cassel, C., Yang, J.P.S. et al. (1975). X-linked recessive progressive combined variable immunodeficiency (Duncan's Disease). Lancet 1, 935-941.
49. Reding, R., Wallemacq, P.E., Lamy, M.E., Rahier, J., Sempoux, C., Debande, B. et al (1994). Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. Transplantation 57, 93-100.
50. Rickinson, A.B. and Kieff, E. (2001). Epstein-Barr virus. In B.N. Fields, D.M. Klipe, P.M. Howley, et al. (eds.) Fields Virology, 3rd Edn. Lippincott-Raven Publishers, Philadelphia, pp. 2575-2627.
51. Riddler, S.A., Breinig, M.C., and McKnight, J.L.C. (1994). Increased levels of circulating EBV + lymphocytes and decreased anti-EBNA antibody responses are associated with the development of post-transplant lymphoproliferative disease in solid organ transplant recipients. Blood 84, 972-984.
52. Rowe, D.T., Qu, L., Reyes, J., Jabbour, N., Yunis, E., Putnam, P. et al (1997). Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in peripheral blood of pediatric transplant recipients with lymphoproliferatice disorders. J. Clin. Microbiol. 35, 1612-1615.
53. Rowe, M. (1995). The EBV latent membrane protein-1 (LMP1): A tale of two functions. EBV Rep. 2, 99-104.
54. Savoie, A., Perpete, C., Carpentier, L., Jonas, J., and Alfieri, C. (1994). Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant recipients and risk of lymphoproliferative disease. Blood 83, 2715-2722.
55. Shapiro, R.S., McClain, K., Frizzera, G., Gajl-Peczalska, K.J., Kersey, J.H., Blazar, B.R. et al. (1998). Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71, 1234-1243.
56. Sonnenfeld, G. (1999). Space flight, microgravity, stress, and immune responses. Adv. Space Res. 23, 1945-1953.
57. Stowe, R.P., Pierson, D.L., and Feeback, D.L. (2000). Stress-induced reactivation of Epstein-Barr virus in astronauts. Neuroimmunomodulation 8(2), 51-58.
58. Sumaya, C.V., Henle, W., Henle, G., Smith, M.H., LeBlanc, D. (1975). Seroepidemiologic study of Epstein Barr virus infections in a rural community. J. Infect. Dis. 131, 403-408.
59. Sumaya, C.V. (1996). Epstein-Barr virus. In J.D. Cherry and R.D. Feign (eds.) Textbook of Pediatric infectious Diseases, 3rd Edn. WB Saunders Company, Philadelphia, pp. 1547-1557.
60. Swinnen, L.J., Costanzo-Nordin, M.R., Fisher, S.G., O'Sullivan, E.J., Johnson, M.R., Heroux, A.L. et al. (1990). Increased incidence of lymphoproliferative disorder after immunosuppression with monoclonal antibody OKT3 in cardiac-transplant recipients. N. Engl. J. Med. 323, 1723-1728.
61. Tosato, G., Straus, S., Henle, W., Pike, S.E., and Blaese, R.M. (1985). Characteristic T cell dysfunction in patients with chronic active EBV infection (chronic infectious mononucleosis) J. Immunol. 134, 33-82.
62. Walker, R.C., Marshall, W.F., Strickler, J.G., Wiesner, R.H., Velosa, J.A., Habermann, T.M. et al (1995). Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin. Infect. Dis. 20, 1345-1353.
63. Zimber, U., Addinger, H.K., Lenoir, G.M., Vuillaume, M., Knebel-Doeberitz, M.V., Laux, G. et al. (1986). Geographical prevalence of two types of Epstein-Barr virus. Virology 154, 56-66.